1
Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Condition(s):Atypical Hemolytic Uremic Syndrome (aHUS)Last Updated:August 1, 2022Active, not recruiting
Complement Inhibitor: 269 Clinical Trials, Page 1 of 27
Hide Studies Not Open or Pending
2
ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Condition(s):Paroxysmal Nocturnal Hemoglobinuria (PNH)Last Updated:November 24, 2021Active, not recruiting
3
Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy
Condition(s):Paroxysmal Nocturnal Hemoglobinuria (PNH)Last Updated:August 2, 2022Recruiting
4
A Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors.
Condition(s):Paroxysmal Nocturnal HemoglobinuriaLast Updated:August 3, 2022Recruiting
5
First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers
Condition(s):Complement Mediated DiseasesLast Updated:January 16, 2018Completed
6
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
Condition(s):Atypical Hemolytic Uremic SyndromeLast Updated:July 15, 2022Recruiting
7
A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.
Condition(s):Paroxysmal Nocturnal HemoglobinuriaLast Updated:August 3, 2022Active, not recruiting
8
Ravulizumab-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy
Condition(s):Paroxysmal Nocturnal HemoglobinuriaLast Updated:May 9, 2022Recruiting
9
Complement Inhibitor Eculizumab in Clinical Islet Transplantation
Condition(s):Diabetes MellitusLast Updated:October 4, 2018Completed
10
BCX9930 for the Treatment of PNH in Subjects Not Receiving Other Complement Inhibitor Therapy
Condition(s):Paroxysmal Nocturnal Hemoglobinuria (PNH)Last Updated:May 6, 2022Active, not recruiting